China Pharma Holdings (CPHI) AI Stock Analysis

• Market Cap: $6.11M
• Dividend Yield: N/A
• Average Volume (3M): 44.38K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.49
• Revenue Growth: -29.64%
• EPS Growth: 73.63%
• Country: US
• Employees: 224
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): -0.07
• Shares Outstanding: 3,262,002
• 10 Day Avg. Volume: 22,416
• 30 Day Avg. Volume: 44,377
• PEG Ratio: 1.25
• Price to Book (P/B): 5.25
• Price to Sales (P/S): 8.98
• P/FCF Ratio: -53.68
• Enterprise Value/Market Cap: 1.91
• Enterprise Value/Revenue: <0.01
• Enterprise Value/Gross Profit: >-0.01
• Enterprise Value/Ebitda: >-0.01
• 1Y Price Target: $1.50
• Price Target Upside: -19.79% Downside
• Rating Consensus: Hold
• Number of Analyst Covering: 1

• Rating: 46 Neutral
• Price Target: $1.50 ▼(-19.79% Downside)

The overall stock score is heavily influenced by poor financial performance, with significant challenges in profitability, high leverage, and inadequate cash flow generation. Technical analysis suggests a bearish trend, though not excessively so, while valuation metrics highlight ongoing losses. The lack of earnings call data and corporate events means these factors do not influence the score.

China Pharma Holdings Business Overview & Revenue Model

Company Description

China Pharma Holdings, Inc. develops, manufactures, and markets generic and branded pharmaceutical, and biochemical products primarily to hospitals and private retailers in the People's Republic of China. The company offers products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. Its products include Cerebroprotein Hydroloysate injection to treat memory decline and attention deficit; Gastrodin injection for tiredness, loss of concentration, poor sleep, and traumatic syndromes of the brain; Propylgallate and Ozagrel Sodium to treat cerebral thrombosis, coronary heart disease, and after surgery complications; Alginic Sodium Diester injection for ischemic heart, cerebrovascular, and high lipoprotein blood diseases; Bumetanide injection to treat edema diseases; and Candesartan for hypertension. It also provides Roxithromycin dispersible tablets for pharyngitis and tonsillitis; Cefaclor dispersible tablets for tympanitis, lower respiratory tract infection, urinary tract infections, and skin/skin tissue infection; Cefalexin capsules for acute tonsillitis; Andrographolide for sore throat caused by upper respiratory tract infection; Clarithromycin granules and capsules; and Naproxen Sodium and PseudophedrineHydrochlorida sustained release tablets. In addition, the company offers Hepatocyte growth-promoting factor, Tiopronin, Compound Ammonium Glycyrrhetate S, and Omeparzole for the treatment of digestive diseases. Further, it provides Vitamin B6 injection; Granisetron Hydrochloride injection to treat nausea and vomiting caused by radiotherapy and chemotherapy during the treatment of malignant tumors; Noni Enzyme, a food supplement; sanitizers; and masks. The company offers its products through distributors, as well as through its network of 16 sales offices and approximately 1,000 sales representatives. China Pharma Holdings, Inc. was founded in 1993 and is based in Haikou, the People's Republic of China.

How the Company Makes Money

China Pharma Holdings generates revenue primarily through the sale of its pharmaceutical products, which include prescription medications and over-the-counter drugs. The company has established partnerships with healthcare providers and distributors, allowing it to broaden its market reach and enhance sales. Key revenue streams include direct sales to hospitals and clinics, distribution agreements with pharmaceutical wholesalers, and export sales to international markets. Additionally, CPHI may benefit from government subsidies and grants aimed at promoting domestic pharmaceutical research and development, further contributing to its earnings.

China Pharma Holdings Financial Statement Overview

Summary

China Pharma Holdings faces significant financial challenges across all verticals. The income statement shows persistent losses and stagnant revenue growth. The balance sheet is burdened with high leverage and negative equity returns, while cash flow analysis reveals inadequate cash generation. The company needs to address these issues to improve financial health and stability.

Income Statement

The income statement reveals significant challenges, with negative margins across the board. The gross profit margin is deeply negative, indicating cost issues or pricing pressures. Net profit margin is also negative, reflecting ongoing losses. Revenue growth is stagnant in the TTM period, suggesting a lack of sales momentum. Overall, the company is struggling to achieve profitability.

Balance Sheet

The balance sheet shows a high debt-to-equity ratio, indicating significant leverage and potential financial risk. Return on equity is negative, reflecting poor returns on shareholder investments. The equity ratio is low, suggesting limited equity buffer against liabilities. Overall, the financial stability is concerning with high leverage and negative returns.

Cash Flow

Cash flow analysis indicates severe issues, with negative free cash flow growth and low operating cash flow coverage. The free cash flow to net income ratio is negative, highlighting cash generation problems relative to losses. Overall, the cash flow situation is precarious, with insufficient cash generation to cover operational needs.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	1.14T	4.53M	7.01M	8.10M	9.64M	10.87M
Gross Profit	-136.06B	-1.99M	-281.08K	-493.92K	349.27K	1.95M
EBITDA	-758.62B	-1.96M	8.44K	-837.69K	230.34K	106.85K
Net Income	-785.57B	-4.74M	-3.08M	-10.22M	-3.94M	-3.16M
Balance Sheet
Total Assets	13.77M	14.89M	16.47M	17.78M	22.65M	21.12M
Cash, Cash Equivalents and Short-Term Investments	625.03K	626.88K	1.42M	2.03M	4.86M	957.65K
Total Debt	3.43M	3.59M	4.63M	8.76M	12.49M	7.43M
Total Liabilities	7.30M	7.14M	9.01M	13.49M	16.63M	13.11M
Stockholders Equity	6.46M	7.75M	7.45M	4.29M	6.02M	8.00M
Cash Flow
Free Cash Flow	70.26K	-758.08K	-711.20K	-811.51K	-687.89K	-909.57K
Operating Cash Flow	424.78K	-466.36K	-699.69K	-409.55K	-249.84K	-42.26K
Investing Cash Flow	-354.52K	-291.72K	-11.52K	-401.96K	-438.06K	-867.31K
Financing Cash Flow	-85.58K	27.35K	73.14K	-1.77M	4.60M	624.18K

China Pharma Holdings Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 1.87
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CPHI, the sentiment is Neutral. The current price of 1.87 is above the 20-day moving average (MA) of 1.79, above the 50-day MA of 1.66, and below the 200-day MA of 1.93, indicating a neutral trend. The MACD of 0.10 indicates Negative momentum. The RSI at 57.10 is Neutral, neither overbought nor oversold. The STOCH value of 73.91 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for CPHI.

China Pharma Holdings Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
UPC	51 Neutral	2.50M	―	-19.18%	―	-27.81%	―
CPHI	46 Neutral	$6.11M	―	-52.05%	―	-29.64%	73.63%
EVOK	46 Neutral	7.64M	-1.71	―	―	70.02%	82.33%
SBFM	46 Neutral	6.65M	-0.56	-24.55%	―	19.22%	98.73%
SNOA	45 Neutral	6.64M	-1.64	-78.37%	―	17.43%	75.52%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

China Pharma Holdings Corporate Events

China Pharma Holdings Announces Reverse Stock Split

On April 4, 2025, China Pharma Holdings announced a 1-for-10 reverse stock split set to take effect on April 15, 2025. This move, authorized by the Board and stockholders, will consolidate every 10 shares into one, affecting all shareholders uniformly without altering their percentage interest in the company.